drugset
Drugs / CKD-828
last change Mar 2024 re-read 2 minutes ago

CKD-828

also known as Telminuvo
Developed for
hypertensive disorder · hyperlipidemia · essential hypertension
Investigated by
Chong Kun Dang Pharmaceutical

Trials 14 · a red edge is where a trial was stopped

today NCT06112678 · Ph 1 NCT05881707 · Ph 1 NCT05834595 · Ph 1 NCT05749861 · Ph 1 NCT05549401 · Ph 1 NCT05540912 · Ph 1 NCT05192356 · Ph 1 NCT04883658 · Ph 1 NCT04660370 · Ph 1 NCT04587206 · Ph 1 NCT04258865 · Ph 1 NCT04388215 · Ph 3 NCT03726866 · Ph 1 NCT02526875 · Ph 4
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 112 trials
Phase 1 NCT06112678 Jan → Feb 2024 hyperlipidemia, hypertensive disorder Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05881707 Jul → Sep 2023 hypertensive disorder Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05834595 May → Jul 2023 hypertensive disorder Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05749861 Apr → Jun 2023 hyperlipidemia, combined, 2 Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05549401 Sep → Nov 2022 — Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05540912 Sep → Nov 2022 hypertensive disorder Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05192356 Feb → May 2022 hyperlipidemia, combined, 2 Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04883658 Jun → Jul 2021 — Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04660370 Jan → Feb 2021 hyperlipidemia, combined, 2 Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04587206 Oct → Dec 2020 — Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 31 trial
Phase 3 NCT04388215 Oct 2019 → Apr 2021 essential hypertension, hyperlipidemia Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT02526875 Apr 2015 → Nov 2017 hypertensive disorder Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04304547 Comparator Feb → Apr 2020 — Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04272502 Background Jun → Aug 2019 — Chong Kun Dang Pharmaceutical Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

FieldValueCited text
Known as CKD-828 “D326, D337 or CKD-828 for 9 days” NCT03726866 ↗
14

NCT05834595 ↗

NCT04304547 ↗

NCT04587206 ↗

NCT04883658 ↗

NCT04272502 ↗

NCT05192356 ↗

NCT05549401 ↗

NCT05540912 ↗

NCT05749861 ↗

NCT04660370 ↗

NCT06112678 ↗

NCT05881707 ↗

NCT04388215 ↗

NCT04258865 ↗
Known as Telminuvo ClinicalTrials.gov intervention name — accepted as the source's own label NCT02526875 ↗
Route Oral “per oral” NCT02526875 ↗